Outcome of Board Meeting held on May 27, 2026

Rossari Biotech's Board of Directors met on May 27, 2026 and approved two key items. First, the Board recommended re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of 3 years from October 21, 2026 to October 20, 2029, subject to shareholder approval. Ms. Esha is a finance professional with 33 years of experience, having held senior roles at Glenmark Pharmaceuticals and Bajaj. Second, the Board approved the grant of 830,050 stock options under the Rossari Employee Stock Option Plan – 2019 (ESOP 2019) to eligible employees at an exercise price of Rs. 537 per option. These options will vest over 4 years with 20% vesting at the end of years 1-3 and 40% at the end of year 4, and can be exercised within 5 years of vesting.